Clinical Trials Logo

Filter by:
NCT ID: NCT03176238 Active, not recruiting - Clinical trials for Post Menopausal Breast Cancer

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

EVEREXES
Start date: March 29, 2013
Phase: Phase 3
Study type: Interventional

The present international, multi-center, open-label, single-arm study aims at collecting clinical safety, tolerability and efficacy data with the use of everolimus combined with exemestane in the Novartis Oncology Emerging Growth Market (EGM) countries for the treatment of post-menopausal women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer after documented recurrence or progression following a non-steroidal aromatase inhibitor (NSAI) therapy.

NCT ID: NCT03069209 Active, not recruiting - Clinical trials for Premature Ovarian Failure

Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)

Start date: January 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label, single arm, single center investigation to assess the safety and efficacy of purified adult autologous bone marrow derived specific populations of stem cells and mesenchymal stem cells injected into the ovaries (intraovarian injection), through a 12 week follow-up period. The investigators' chosen model of study is based on increasing the efficiency of the approach by choosing an autologous model which preserves the genetic composition of an individual that is vital in infertility conditions. Additionally the approach involves transplanting a combination of specific purified stem cell types which all aid in ovarian function recovery.

NCT ID: NCT03069170 Active, not recruiting - Multiple Sclerosis Clinical Trials

Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.

Start date: July 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Until now, there is no effective approach to stop the progression of multiple sclerosis and stimulate re-myelination. Autologous stem cell transplantation shows hope and is quickly developing as an alternative therapy. We propose the use of autologous bone marrow-derived specific stem cell populations and mesenchymal stem cell transplantation (BM-MSC) associated with immuno-modulation to treat patients with relapsing-remitting MS (RRMS).

NCT ID: NCT03066245 Recruiting - Clinical trials for Aneurysmal Bone Cyst

Use of Stem Cells Cultured on a Scaffold for the Treatment of Aneurysmal Bone Cysts (ABC)

Start date: October 3, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Patients qualified for this study are those diagnosed with ABCs and failed to be treated with other forms of classical therapies. In which, these patients will be engrafted with biodegradable scaffolds seeded with Mesenchymal Stem Cells (MSCs) supplemented with Platelet lysate.

NCT ID: NCT03015831 Not yet recruiting - Atrial Fibrillation Clinical Trials

Effect of Low Dose ColchiciNe on the InciDence of POAF

END-AFLD
Start date: March 2017
Phase: Phase 3
Study type: Interventional

The prior End-AF study by the same group showed that 1 mg of colchicine didn't decrease the incidence of AF after cardiac surgery. The current study, End-AF Low Dose Study, will test 0.5 mg colchicine vs. placebo in preventing AF after cardiac surgery.

NCT ID: NCT02981576 Active, not recruiting - Clinical trials for Spinal Cord Injuries

Safety and Effectiveness of BM-MSC vs AT-MSC in the Treatment of SCI Patients.

Start date: November 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Spinal Cord Injury (SCI) is a devastating condition that leads to permanent functional and neurological deficits in injured individuals. The limited ability of the Central Nervous System (CNS) to spontaneously regenerate impairs axonal regeneration and functional recovery of the spinal cord. The leading causes are motor-vehicle crashes, sports-associated accidents, falls, and violence-related injuries. Unfortunately, there is still no effective clinical treatment for SCI. In recent years, tissue engineering and regenerative medicine based approaches have been proposed as alternatives for SCI repair/regeneration. Mesnchymal stem cells (MSC) use in SCI showed promising results in several studies. Our aim is to assess and compare the safety and effectiveness of autologous BM-MSC vs autologous AT-MSC in these patients.

NCT ID: NCT02980757 Withdrawn - Clinical trials for Comparative Bioavailability

Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets

Start date: June 2014
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to assess comparative bioavailability of two test formulations of Gliclazide 120 mg Modified Release tablets (120 mg gliclazide per modified release tablet) Manufactured By Indeus Life Sciences Pvt. Ltd., Mumbai India (An Affiliate Of Disphar International B.V., The Netherlands) Relative To DIAMICRON MR® 60 mg 2 × (60 mg gliclazide per modified release tablet) Of Les Laboratories Servier Industrie, France in 15 healthy adult subjects under fasting conditions. The second aim is to asses the safety of subjects and to determine other pharmacokinetic data.

NCT ID: NCT02979912 Recruiting - Clinical trials for Persistent Corneal Epithelial Defect

Autologous Platelet Lysate in Corneal Epithelial Defects

Start date: February 16, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Patients diagnosed with persistent corneal epithelial ulcers will be treated with autologous platelet lysate.

NCT ID: NCT02977312 Completed - Clinical trials for Chronic Myeloid Leukemia, Chronic Phase

Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan

CCMLJ
Start date: August 2012
Phase: N/A
Study type: Observational

This study assessed the efficacy and safety of generic imatinib in patients with chronic myeloid leukemia (CML) in Jordan. It was a multicenter, non-interventional, open-label, prospective study combined with retrospective data collection from files of patients with a diagnosis of Ph+ CML, treated with Cemivil (imatinib), where no visits or intervention(s) additional to the daily practice were performed

NCT ID: NCT02972528 Recruiting - Diabetic Foot Ulcer Clinical Trials

The Use of Allogenic Platelet Rich Plasma for the Treatment of Diabetic Foot Ulcer

Start date: February 3, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Allogenic defibrinated platelet rich plasma lysate will be injected in patients diagnosed with Diabetic Foot Ulcer (DFU).